title: Biologic and New Therapies in Asthma.
abstract: Several biologics are currently FDA approved for asthma that target Th2 high patients. Unfortunately, 50% of patients with severe asthma do not fit this phenotype of disease and have fewer effective therapeutic options. In the clinical setting, total IgE, FeNO and peripheral blood eosinophils are important tools in defining Th2 high patients with asthma. However, precise biomarkers to predict better response to one specific Th2 high asthma therapy versus another is lacking. It is important to recognize that none of the current medications targeting the Th2 pathway induces persistent immunomodulation or remission.
authors.affiliation: Division of Allergy and Immunology, Department of Internal medicine, Morsani College of Medicine, University of South Florida, 13330 USF Laurel Dr. 5th Floor, MDC 80, Tampa, FL 33612-4799, USA.
authors.forename: Farnaz
authors.initials: F
authors.lastname: Tabatabaian
authors.affiliation: Division of Allergy and Immunology, Department of Internal medicine, Morsani College of Medicine, University of South Florida, 13330 USF Laurel Dr. 5th Floor, MDC 80, Tampa, FL 33612-4799, USA; Division of Allergy and Immunology, Department of Internal Medicine, Morsani College of Medicine, James A. Haley VA Hospital, University of South Florida, 13000 Bruce B, Downs Boulevard, Tampa, FL 33612, USA.
authors.forename: Dennis K
authors.initials: DK
authors.lastname: Ledford
authors.affiliation: Division of Allergy and Immunology, Department of Internal medicine, Morsani College of Medicine, University of South Florida, 13330 USF Laurel Dr. 5th Floor, MDC 80, Tampa, FL 33612-4799, USA; Division of Allergy and Immunology, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, 12901 Bruce B Downs Boulevard, MDC 19, Tampa, FL 33612 USA. Electronic address: tbcasale@health.usf.edu.
authors.forename: Thomas B
authors.initials: TB
authors.lastname: Casale
mesh_terms: D018927:Anti-Asthmatic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D001688:Biological Products / Q000494:pharmacology / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D058990:Molecular Targeted Therapy; D015398:Signal Transduction / Q000187:drug effects; D018418:Th2 Cells / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D018927:Anti-Asthmatic Agents; D000911:Antibodies, Monoclonal; D001688:Biological Products; D015415:Biomarkers; D016207:Cytokines
keywords: Anti-IL-13; Anti-IL-4; Anti-IL-5; Anti-IgE; Asthma; Biologics; CRTH2; Th2